期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 27, 期 23, 页码 3317-3326出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i23.3317
关键词
Inflammatory bowel disease; Dysbiosis; Fecal microbiota transplantation; Short chain fatty acid; Probiotics
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, involving Crohn's disease and ulcerative colitis, with aberrant immune activation possibly caused by genetic susceptibility and environmental factors. Studies have shown dysbiosis and altered metabolites from the gut microbiota to play a role in IBD pathogenesis. Interventions like fecal microbiota transplantation (FMT) are being explored as novel therapies for IBD, but their efficacy is still debated, requiring further research validation.
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract encompassing two main clinical entities, Crohn's disease and ulcerative colitis. Accumulated evidence indicates that an aberrant immune activation caused by the interplay of genetic susceptibility and environmental impact on the gut microbiota may be involved in the pathogenesis of IBD. Rapid advances in next-generation sequencing technology have enabled a number of studies to identify the alteration of the gut microbiota, termed dysbiosis, in IBD. Moreover, the alteration in the metabolites derived from the gut microbiota in IBD has also been described in many studies. Therefore, microbiota-based interventions such as fecal microbiota transplantation (FMT) have attracted attention as a novel therapeutic option in IBD. However, in clinical trials, the efficacy of FMT for IBD remains controversial. Additional basic and clinical studies are required to validate whether FMT can assume a complementary role in the treatment of IBD. The present review provides a synopsis on dysbiosis in IBD and on the association between the gut microbiota and the pathogenesis of IBD. In addition, we summarize the use of probiotics in IBD and the results of current clinical trials of FMT for IBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据